Sunday, September 29, 2024
HomeTagsOral PD-L1

Oral PD-L1

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1

Ascletis Pharma Inc. announces the completion of first patient dosing in the U.S. Phase I clinical trial of ASC61, an oral PD-L1 small molecule...

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

Ascletis Pharma Inc.  announces the approval of the Investigational New Drug (IND) application by U.S. Food and Drug Administration (FDA) for in-house developed oral...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics